The 13 patients were to get 2 cycles of Adcetris prior to beginning CHOP. From what is said, it appears that the CHOP may have prevented several from continuing (1 patient was in their 80's) and may have done more harm than good. Given this data a patient may have been better off to continue on the single-agent Adcetris IMO. I hope others will see it that way too.
The 10 ALK- have a poorer prognosis than the 3 ALK+. Not included is the very telling NUC positive or negative which is more prognostic than the ALK. Maybe they will add that info in their next release.
SGEN Oct 1
"*Of the 13 evaluable patients on Arm 1 of the study, 100 percent achieved an objective response following the first two cycles of treatment with single-agent brentuximab vedotin, including five CRs and eight PRs
*After eight cycles of sequential therapy, including two cycles of brentuximab vedotin followed by six cycles of CHOP, 11 patients had an objective response, including eight CRs and three PRs
Objective responses were generally maintained in patients treated with single-agent brentuximab vedotin following CHOP, including seven of nine evaluable patients with CRs at Cycle 12 and five of five evaluable patients with CRs at Cycle "